National Influenza and COVID-19 surveillance report
Week 46 report (up to week 45 data)
16 November 2023
# Contents

Executive summary ................................................................................................................................. 4
Laboratory surveillance .............................................................................................................................. 6
  Respiratory DataMart system (England) ................................................................................................. 6
  Confirmed COVID-19 cases (England) ................................................................................................. 12
Microbiological surveillance ................................................................................................................... 15
  SARS-CoV-2 variants ............................................................................................................................. 15
  Influenza virus characterisation .......................................................................................................... 18
  Influenza antiviral susceptibility .......................................................................................................... 19
Community surveillance .......................................................................................................................... 20
  Acute respiratory infection incidents .................................................................................................... 20
  Google search queries ........................................................................................................................... 23
  Flu Detector ........................................................................................................................................... 24
  Syndromic surveillance .......................................................................................................................... 25
Primary care surveillance ........................................................................................................................ 29
  RCGP Clinical Indicators (England) .................................................................................................... 29
  RCGP sentinel swabbing scheme in England ...................................................................................... 30
Secondary care surveillance ...................................................................................................................... 34
  Influenza, SARI Watch ........................................................................................................................ 34
  COVID-19, SARI Watch ....................................................................................................................... 41
  ECMO, SARI Watch .............................................................................................................................. 46
  RSV admissions, SARI Watch ............................................................................................................. 47
Mortality surveillance .............................................................................................................................. 50
  COVID-19 deaths .................................................................................................................................. 50
  Daily excess all-cause mortality (England) ........................................................................................... 50
Influenza vaccination .............................................................................................................................. 51
  Influenza vaccine uptake in GP patients ............................................................................................... 51
COVID-19 vaccination ............................................................................................................................ 53
  COVID-19 vaccine uptake in England ................................................................................................ 53
International update ............................................................................................................................... 58
For additional information including regional data on COVID-19 and other respiratory viruses, COVID-19 in educational settings, co- and secondary infections with COVID-19 and other data supplementary to this report, please refer to the accompanying graph pack.

For additional information regarding data source please refer to Sources of surveillance data for influenza, COVID-19 and other respiratory viruses.
Executive summary

This report summarises the information from the surveillance systems which are used to monitor COVID-19 (caused by SARS-CoV-2), influenza, and diseases caused by seasonal respiratory viruses in England. References to COVID-19 represent the disease name and SARS-CoV-2 represent the virus name. The report is based on data from week 45 (between 6 November and 12 November 2023).

Overall

In week 45, influenza activity is still at low levels with some suggestion of increasing activity in children. COVID-19 activity decreased in almost all indicators. Overall respiratory syncytial virus (RSV) activity increased, with possible signs of stabilisation in some indicators in children under 5 years of age after marked increases in recent weeks.

Influenza

Through Respiratory DataMart, influenza positivity remained stable at 1.8% in week 45 compared to 1.6% in the previous week, with increased in positivity in school-aged children.

Through primary care surveillance, the influenza-like-illness (ILI) consultations indicator remained stable at 3.8 per 100,000 in week 45 compared to 3.3 per 100,000 the previous week and was within the baseline activity level range.

There were no influenza confirmed outbreaks reported in England in week 45.

Overall, influenza hospitalisations remained within baseline activity levels in week 45. Influenza intensive care unit (ICU) or high dependency unit (HDU) admissions remained within baseline activity levels compared to the previous week. There were 2 new influenza ICU or HDU admissions in week 45.

Emergency department (ED) attendances for influenza-like illness remained stable nationally.

Weekly Influenza vaccine uptake for the 2023 to 2024 season is reported for the sixth time. Compared to the equivalent week in the 2022 to 2023 season, vaccine uptake remains higher for those aged 65 years and over, pregnant women and 2 and 3 year olds; but is lower for those under 65 years in clinical risk groups. Next week monthly vaccine uptake data will be reported for the first time this season for GP patients, school-aged children and frontline healthcare workers.

COVID-19

Through Respiratory DataMart, SARS-CoV-2 positivity decreased to 6.6% in week 45 compared to 7.3% in the previous week.
COVID-19 case rates and positivity rates through Pillar 1 decreased in most age groups, regions and ethnic groups in week 45.

The overall number of reported SARS-CoV-2 confirmed outbreaks increased compared to the previous week. There were 9 SARS-CoV-2 confirmed outbreaks reported in week 45 in England.

Overall, COVID-19 hospitalisations decreased to 2.8 per 100,000 in week 45 compared to 3.4 per 100,000 in the previous week. Hospitalisations were highest in the 85 years and over age group. COVID-19 ICU admissions remained low and stable in week 45 compared to the previous week.

Through syndromic surveillance indicators, emergency department attendances for COVID-19-like illness continued to decrease nationally.

**RSV**

Through Respiratory DataMart, positivity for RSV increased to 10.9%, with the highest positivity in those aged under 5 years old at 36.3%. ED attendances for acute bronchiolitis continued to increase nationally. Overall, RSV hospitalisations increased to 2.6 per 100,000 compared to 2.3 per 100,000 in the previous week. The highest rate was seen in the under 5 year olds at 35.1 per 100,000, which increased slightly from 32.2 per 100,000 in the previous week.

**Other viruses**

Adenovirus positivity remained low at 2.0%, with the highest positivity in children under 5 years old at 5.3%. Human metapneumovirus (hMPV) positivity increased to 1.6%, with the highest positivity in children under 5 years old at 2.9%. Parainfluenza positivity remained low at 1.2%, with the highest positivity in children under 5 years old at 2.1%. Rhinovirus positivity increased to 13.5% overall, with the highest positivity in children under 5 years old at 22.7%.
Laboratory surveillance

Respiratory DataMart system (England)

In week 45, data is based on reporting from 12 out of the 16 sentinel laboratories.

In week 45, 5,044 respiratory specimens reported through the Respiratory DataMart System were tested for influenza. There were 89 positive samples for influenza; 48 influenza A (not subtyped), 25 influenza A(H3N2), 2 were influenza A(H1N1)pdm09 and 14 were influenza B (Figure 4). Overall, influenza positivity remained stable at 1.8% in week 45 compared to 1.6% in the previous week.

In week 45, 5,093 respiratory specimens reported through the Respiratory DataMart System were tested for SARS-CoV-2. There were 334 positive samples for SARS-CoV-2 with an overall positivity of 6.6%, which decreased compared to 7.3% in the previous week. The highest positivity was seen in adults aged over 65 years at 9.0%.

RSV positivity increased slightly to 10.9%, with the highest positivity in those aged under 5 years old at 36.3%.

Adenovirus positivity remained low at 2.0%, with the highest positivity in children under 5 years old at 5.3%.

Human metapneumovirus (hMPV) positivity increased to 1.6%, with the highest positivity in children under 5 years old at 2.9%.

Parainfluenza positivity remained low at 1.2%, with the highest positivity in children under 5 years old at 2.1%.

Rhinovirus positivity increased to 15.2% overall, with the highest positivity in children under 5 years old at 22.7%.
Figure 1: Respiratory DataMart weekly positivity (%) for a) influenza, SARS-CoV-2, RSV and rhinovirus and b) adenovirus, hMPV and parainfluenza, England

a)

b)
Figure 2: Respiratory DataMart weekly positivity (%) for influenza by year, England

Please note data from seasons 2020 to 2021 and 2021 to 2022 has been removed as there was low activity throughout these seasons.

Figure 3: Respiratory DataMart samples positive for influenza by type and subtype, England
Figure 4: Respiratory DataMart weekly positivity (%) for influenza by age, England
Figure 5: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by year, England

![Figure 5: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by year, England](image)

Figure 6: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by age, England

![Figure 6: Respiratory DataMart weekly positivity (%) for SARS-CoV-2 by age, England](image)
Figure 7: Respiratory DataMart weekly positivity (%) for RSV by year, England

Figure 8: Respiratory DataMart weekly positivity (%) for RSV by age, England
Confirmed COVID-19 cases (England)

As of 9am on 14 November 2023, a total of 2,152,793 episodes have been confirmed for COVID-19 in England under Pillar 1, and 18,849,774 episodes under Pillar 2, since the beginning of the pandemic. COVID-19 case rates through Pillar 1 decreased in week 45.

There were a total of 3,314 cases in week 45, a 40% decrease from the previous week. Case rates were highest in the over 80 age group, with 17.5 cases per 100,000, (a decrease from 27.9 per 100,000 in week 44) and in the North West, with 3.0 cases per 100,000 (a decrease from 5.1 per 100,000 in week 44).

Data notes: Changes to testing policies over time may affect positivity rates and incidence rates and should be interpreted accordingly. COVID-19 case reporting in England uses an episode-based definition which includes possible reinfections, each infection episode is counted separately if there are at least 91 days between positive test results (polymerase chain reaction (PCR) or rapid lateral flow device). Each infection episode begins with the earliest positive specimen date. Additionally, further changes in testing policy are in effect since 1 April 2023, which may affect case rates and positivity rates.

Figure 9: Confirmed COVID-19 episodes tested under Pillar 1, based on sample date with overall seven-day rolling average PCR positivity for Pillar 1 (%)

The vertical dashed line (red) denotes changes in testing policies.
Age

Figure 10: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by age group

Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

Geography

Figure 11: Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested under Pillar 1 by UKHSA region

Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Ethnicity

Figure 12: Weekly incidence of confirmed COVID-19 cases per 100,000 population by ethnicity (Pillar 1), England

Please note the highlighted line corresponds to the ethnicity in the subplot title, grey lines correspond to all other ethnicities.
Microbiological surveillance

SARS-CoV-2 variants

This section is updated fortnightly with updated data presented in this report. This week’s report contains no update.

UK Health Security Agency (UKHSA) conducts genomic surveillance of SARS-CoV-2 variants.

This section provides an overview of new and current circulating variants in England.

Detailed surveillance of particular variants of concerns can be found in recent technical briefings.

Information on whole genome sequencing coverage can be found in the accompanying slide set.

The prevalence of different UKHSA-designated variants amongst sequenced cases is presented in Figure 13.

To account for sequencing delays, we report the proportion of variants from sequenced cases between 23 October 2023 and 29 October 2023. Of those sequenced in this period, 25.7% were classified as XBB (V-22OCT-02), 6.8% as XBB.1.5 (V-23JAN-01), 19.8% as XBB.1.16 (V-23APR-01), 34.7% as EG.5.1 (V-23JUL-01), 10.9% as BA.2.86 (V-23AUG-01).
Figure 13: Prevalence of SARS-CoV-2 variants amongst available sequences cases for England from 7 November 2022 to 12 November 2023

The grey line indicates proportion of cases sequenced.
The vertical dashed line (red) in April 2023 denotes changes in PCR testing in social care and hospital settings.
Table 1. Total distribution of SARS-CoV-2 variants detected in England in the last 12 weeks, up to week 45 (week ending 12 November 2023)

<table>
<thead>
<tr>
<th>Variant</th>
<th>Other names by which this variant is known</th>
<th>Total confirmed (sequencing) cases in the last 12 weeks</th>
<th>Last reported specimen date</th>
</tr>
</thead>
<tbody>
<tr>
<td>VOC-21NOV-01</td>
<td>Omicron BA.1</td>
<td>1</td>
<td>05-10-2023</td>
</tr>
<tr>
<td>V-22JAN-01</td>
<td>Omicron BA.2</td>
<td>51</td>
<td>26-10-2023</td>
</tr>
<tr>
<td>V-22APR-04</td>
<td>Omicron BA.5</td>
<td>7</td>
<td>26-10-2023</td>
</tr>
<tr>
<td>V-22JUL-01</td>
<td>Omicron BA.2.75</td>
<td>1</td>
<td>25-08-2023</td>
</tr>
<tr>
<td>V-22OCT-01</td>
<td>Omicron BQ.1</td>
<td>17</td>
<td>12-10-2023</td>
</tr>
<tr>
<td>V-22OCT-02</td>
<td>Omicron XBB</td>
<td>3433</td>
<td>30-10-2023</td>
</tr>
<tr>
<td>V-22DEC-01</td>
<td>Omicron CH.1.1</td>
<td>245</td>
<td>28-10-2023</td>
</tr>
<tr>
<td>V-23JAN-01</td>
<td>Omicron XBB.1.5</td>
<td>900</td>
<td>30-10-2023</td>
</tr>
<tr>
<td>V-23APR-01</td>
<td>Omicron XBB 1.16</td>
<td>3362</td>
<td>30-10-2023</td>
</tr>
<tr>
<td>V-23JUL-01</td>
<td>Omicron EG.5.1</td>
<td>4202</td>
<td>30-10-2023</td>
</tr>
<tr>
<td>V-23AUG-01</td>
<td>Omicron BA.2.86</td>
<td>412</td>
<td>30-10-2023</td>
</tr>
</tbody>
</table>

Sequencing data has a lag of approximately 2 weeks therefore the data presented should be interpreted in this context.
Cumulative numbers may be revised up or down as a result of reclassification.
Influenza virus characterisation

UKHSA characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation.

As of week 45 2023, the UKHSA Respiratory Virus Unit (RVU) has genetically characterised 22 influenza A(H3N2) viruses, which were detected since week 34. Sequencing of the haemagglutinin (HA) gene shows that these A(H3N2) viruses belong in genetic subclade 3C.2a1b.2a.2 in the 2a.3a.1 subgroup. The Northern Hemisphere 2023/24 influenza A(H3N2) vaccine strain (an A/Darwin/9/2021-like virus) also belongs in genetic subclade 3C.2a1b.2a.2.

20 influenza A(H1N1)pdm09 viruses have been characterised to date this season, with 14 belonging in genetic subgroup 6B.1A.5a.2a and 6 in subgroup 6B.1A.5a.2a.1. The Northern Hemisphere 2023/24 influenza A(H1N1)pdm09 vaccine strain (an A/Victoria/4897/2022 (H1N1)pdm09-like virus) also belongs in genetic subclade 6B.1A.5a, within the 6B.1A.5a.2a.1 cluster.

One influenza B/Victoria lineage virus has been genetically characterised belonging in subclade V1A3, within the subgroup V1A3a.2. The Northern Hemisphere 2023/24 influenza B/Victoria lineage vaccine strain (a B/Austria/1359417/2021-like virus) also belongs in this V1A3a.2 subclade/group.

At this early stage of the influenza season, it is too early to predict which influenza lineages will dominate throughout the season, and a close watch will be kept on the proportion of different viruses circulating to assist with the evaluation of vaccine effectiveness.

The RVU has confirmed by genome sequencing the detection of live attenuated influenza vaccine (LAIV) viruses in 3 influenza A positive samples and in 3 influenza B positive samples collected since week 40, from children aged between 2 and 16 years of age.
Table 2: Number of influenza viruses characterised by genetic and antigenic analysis at the UKHSA Respiratory Virus Unit since week 34/2023

<table>
<thead>
<tr>
<th>(Sub)type</th>
<th>Total number characterised</th>
<th>Genetic characterisation: genetic group</th>
<th>Genetic characterisation: number sequenced</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H3N2)</td>
<td>22</td>
<td>3C.2a1b.2a.2a.3a.1</td>
<td>22</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>20</td>
<td>6B.1A.5a.2a</td>
<td>14</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>20</td>
<td>6B.1A.5a.2a.1</td>
<td>6</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>1</td>
<td>V1A3a.2</td>
<td>1</td>
</tr>
</tbody>
</table>

Influenza antiviral susceptibility

Influenza positive samples are genome sequenced and screened for mutations in the virus neuraminidase (NA) and the cap-dependent endonuclease (PA) genes known to confer neuraminidase inhibitor or baloxavir resistance, respectively. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with antiviral-resistant virus is also performed.

Influenza virus sequences from samples collected between weeks 34 of 2023 and 45 of 2023 have been analysed. Analysis of 22 influenza A(H3N2) viruses found no viruses with known markers of resistance to neuraminidase inhibitors. Analysis of 16 influenza A(H1N1)pdm09 by sequencing found one oseltamivir resistant virus with an H275Y amino acid substitution (99% H275Y). The sample was collected from an immune compromised adult who was known to have received oseltamivir treatment. Analysis of one influenza B NA sequence found no evidence of known markers of resistance to neuraminidase inhibitors.

No viruses with known markers of resistance to baloxavir marboxil were detected in 20 A(H3N2), 13 A(H1N1)pdm09 and one influenza B PA sequences analysed.

Table 3: Antiviral susceptibility of influenza positive samples tested at UKHSA-RVU

<table>
<thead>
<tr>
<th>(Sub)type</th>
<th>Neuraminidase inhibitors: susceptible</th>
<th>Neuraminidase inhibitors: reduced susceptibility</th>
<th>Baloxavir: susceptible</th>
<th>Baloxavir: reduced susceptibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>A(H3N2)</td>
<td>22</td>
<td>0</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>A(H1N1)pdm09</td>
<td>16</td>
<td>1</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>B/Victoria-lineage</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>
Community surveillance

Acute respiratory infection incidents (ARI)

Here we present data on acute respiratory infection (ARI) incidents in different settings that are reported to UKHSA Health Protection Teams (HPTs).

There were 50 new ARI incidents reported in week 45 in England, including:

- 41 incidents reported from care homes, where 7 had at least one linked case that tested positive for SARS-CoV-2 and one tested positive for rhinovirus
- 5 incidents reported from hospitals, where 2 had at least one linked case that tested positive for SARS-CoV-2
- 3 incidents reported from educational settings, where 2 had at least one linked case that tested positive for RSV
- one incident from other settings, where no positive test was available

Figure 14: Number of ARI incidents by setting, England
Figure 15: Number of ARI incidents in all settings by virus type, England

Figure 16: Number of ARI incidents in care homes by virus type, England
Figure 17: Number of ARI incidents in educational settings by virus type, England
Google search queries

This is a web-based syndromic surveillance system which uses daily search query frequency statistics obtained from the Google Health Trends API (Application Programming Interface). This model focuses on search queries about COVID-19 symptoms as well as generic queries about ‘coronavirus’ (for example ‘COVID-19’). The search query frequency time series is weighted based on symptom frequency as reported in other data sources. Frequency of searches for symptoms is compared with a baseline calculated from historical daily data. Further information on this model is available online.

During week 45, the overall and media-debiasing weighted Google search scores remained stable compared to the previous week (Figure 18).

Figure 18: Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England
Flu Detector

FluDetector is a web-based model which assesses internet-based search queries for influenza-like illness (ILI) in the general population.

Daily ILI rate estimates are based on uniformly averaged search query frequencies for a week-long period (including the current day and the 6 days before it).

For week 45, the daily ILI rate was low and below the baseline threshold of 10.25 per 100,000 for the 2023 to 2024 season (Figure 19).

Figure 19: Daily estimated ILI Google search query rates per 100,000 population, England
Syndromic surveillance

During week 45, NHS 111 calls for cough increased in infants under one year old, calls for cold or flu remained stable and below baseline levels. GP in hours consultation rates for ILI remained stable and similar to seasonally expected levels. ED for ARI continued to increase nationally and particularly in infants aged under 5 years (Figure 20). ED attendances for ILI remained stable nationally (Figure 21). ED attendances for acute bronchiolitis continued to increase nationally, particularly in children aged under 5 years (Figure 22), but with preliminary signs of stabilisation. ED for COVID-19-like illness continued to decrease nationally.

For further information on syndromic surveillance please see the Syndromic Surveillance: weekly summaries.
Figure 20: Daily ED attendances for acute respiratory infection, England (a) nationally, (b) by age group

(a)

EDSSS: acute respiratory infection 13/11/2022 to 12/11/2023

Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b)

EDSSS: acute respiratory infection by age (years) 13/11/2022 to 12/11/2023

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Figure 21: Daily ED attendances for influenza-like illness, England (a) nationally, (b) by age group

(a)

EDSSS: influenza-like illness 13/11/2022 to 12/11/2023

Black line is 7 day moving average adjusted for bank holidays.
Black dotted line is baseline. Grey columns show weekends and bank holidays.

(b)

EDSSS: influenza-like illness by age (years) 13/11/2022 to 12/11/2023

NOTE: SCALES MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.
Figure 22: Daily ED attendances for acute bronchiolitis, England (a) nationally, (b) by age group*

(a)

EDSSS: acute bronchiolitis 13/11/2022 to 12/11/2023

<table>
<thead>
<tr>
<th>Date</th>
<th>under 1</th>
<th>1 to 4</th>
<th>5 to 14</th>
<th>15 to 44</th>
<th>45 to 64</th>
<th>over 65</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb 23</td>
<td>300</td>
<td>60</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Mar 23</td>
<td>200</td>
<td>40</td>
<td>8</td>
<td>3</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Apr 23</td>
<td>100</td>
<td>20</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>May 23</td>
<td>50</td>
<td>10</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Jun 23</td>
<td>30</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Jul 23</td>
<td>20</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Aug 23</td>
<td>10</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sep 23</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Oct 23</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Nov 23</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dec 23</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

NOTE: SCALING MAY VARY IN EACH GRAPH TO ENABLE TREND COMPARISON.
Black line is 7 day moving average adjusted for bank holidays.

(b)

EDSSS: acute bronchiolitis by age (years) 13/11/2022 to 12/11/2023

*Please note, there was no update in week 14 for acute bronchiolitis syndromic surveillance.
Primary care surveillance

RCGP Clinical Indicators (England)

The weekly ILI consultation rate through the Royal College of General Practitioners (RCGP) surveillance increased slightly to 3.8 per 100,000 registered population in participating GP practices in week 45 compared to 3.3 per 100,000 in the previous week. This is within baseline activity levels (less than 10.25 per 100,000) (Figure 23). By age group, the highest rates were seen those aged below 1 years old (6.5 per 100,000) followed by those aged between 15 and 44 years (4.5 per 100,000). The lower respiratory tract infections (LRTI) consultation rate increased slightly to 89.1 per 100,000 in week 45 compared to 83.9 per 100,000 in the previous week.

Figure 23: RCGP ILI consultation rates, all ages, England

Moving Epidemic Method (MEM) thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.
RCGP sentinel swabbing scheme in England

Based on the date samples were received in the reference laboratory, in week 45 2023 (week commencing 6 November 2023) 673 samples were tested through the GP sentinel swabbing scheme in England, of which 110 samples tested positive (Figure 24). Among all positive samples, 39.1% were positive for rhinovirus, 31.3% for RSV, 14.8% for SARS-CoV-2, 7.8% for hMPV, 3.5% for influenza, 1.7% for other seasonal coronaviruses and 1.7% for adenovirus (Figure 25).

Based on the date samples were taken, positivity for RSV was 13.4%, positivity for influenza was 1.3% and positivity for SARS-CoV-2 was 0.0% in week 45 (Figure 26). Please note data form the most recent week is based on a low amount of tests and will be updated retrospectively.
Figure 24: Number of samples tested for SARS-CoV-2, influenza, and other respiratory viruses in England by week, GP sentinel swabbing

Unknown category corresponds to samples with no result yet.

Source: RCGP Research and Surveillance Centre sentinel primary care practices (RCGP Virology Dashboard)
Figure 25: Proportion of detections of SARS-CoV-2, influenza, and other respiratory viral strains amongst virologically positive respiratory surveillance samples in England by week, GP sentinel swabbing scheme

Source: RCGP Research and Surveillance Centre sentinel primary care practices (RCGP Virology Dashboard)
Figure 26: Weekly positivity (%) for COVID-19, influenza and RSV in England, GP sentinel swabbing

- SARS-CoV-2 positivity (%)
- Total influenza positivity (%)
- RSV positivity (%)

Sample week

0.0 10.0 20.0 30.0 40.0 50.0

Positivity (%)
Secondary care surveillance

Influenza, SARI Watch

Surveillance of influenza hospitalisations to all levels of care is based on data from a small sentinel network of acute NHS trusts in England. Surveillance of admissions to ICU or HDU for influenza is mandatory with data required from all acute NHS trusts in England. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 45 (ending 12 November 2023), the overall weekly hospital admission rate for influenza remained low at 0.29 per 100,000 compared to 0.37 per 100,000 in the previous week. The rate in the latest week remained within baseline activity levels. There were 26 new hospital admissions for influenza (14 influenza A(not subtyped), 5 influenza A(H3N2), 3 influenza A(H1N1)pdm09 and 4 influenza B).

In week 45, the overall ICU or HDU rate for influenza remained low at 0.01 per 100,000 compared to 0.01 per 100,000 in the previous week. The rate in the latest week remained within baseline activity levels. There were 5 new case reports of an ICU or HDU admission for influenza in week 45 (3 influenza A(not subtyped), one influenza A(H1N1)pdm09 and one influenza B).
Figure 27: Weekly overall influenza hospital admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England

MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

Influenza hospital admission rate based on 22 sentinel NHS trusts for week 45.

SARI Watch data is provisional and subject to retrospective updates.
Figure 28: Weekly influenza hospital admissions by influenza type, reported through SARI Watch, England

Number of influenza hospital admissions based on sentinel NHS trusts.

Figure 29: Weekly hospital admission rate by UKHSA region for new influenza reported through SARI Watch*

*Rates in some regions may not include all influenza surveillance sentinel sites from week to week. *Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Figure 30: Weekly hospital admission rate by age group for new influenza reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis

Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.
Figure 31: Weekly overall influenza ICU or HDU admission rates per 100,000 trust catchment population with MEM thresholds, reported through SARI Watch, England

MEM thresholds are based on data from the 2015 to 2016 to the 2022 to 2023 seasons. Please note the 2020 to 2021 and 2021 to 2022 seasons have been removed due to low activity throughout these seasons.

Influenza ICU or HDU admission rate based on 91 NHS trusts for week 45.

SARI Watch data is provisional and subject to retrospective updates.
Figure 32: Weekly influenza ICU or HDU admissions by influenza type, reported through SARI Watch, England

Figure 33: Weekly ICU or HDU admission rate by UKHSA region for new influenza, reported through SARI Watch

Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Figure 34: Weekly ICU or HDU admission rate by age group for new influenza cases, reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis

Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.
COVID-19, SARI Watch

Surveillance of COVID-19 hospitalisations to all levels of care and surveillance of admissions to ICU or HDU for COVID-19 are both mandatory with data required from all acute NHS trusts in England. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 45 (ending 12 November 2023), the overall weekly hospital admission rate for COVID-19 decreased to 2.84 per 100,000 compared to 3.43 per 100,000 in the previous week. By UKHSA region, the highest hospital admission rate for COVID-19 was observed in the North West. By age group, the highest hospital admission rate for COVID-19 continues to be in those aged 85 years and over.

In week 45 (ending 12 November 2023), the overall weekly ICU or HDU admission rate for COVID-19 remained low at 0.12 per 100,000, compared to 0.10 per 100,000 in the previous week. Note that ICU or HDU admission rates may represent a lag from admission to hospital to an ICU or HDU ward. The ICU or HDU admission rate for COVID-19 by UKHSA region or by age group fluctuated at low levels in week 45 due to low underlying numbers.

Figure 35: Weekly overall COVID-19 hospital admission rates per 100,000 trust catchment population, reported through SARI Watch, England

COVID-19 hospital admission rate based on 88 NHS trusts for week 45.

SARI Watch data is provisional and subject to retrospective updates.
Figure 36: Weekly hospital admission rate by UKHSA region for new COVID-19 positive cases, reported through SARI Watch*

*Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Figure 37: Weekly hospital admission rate by age group for new COVID-19 positive cases reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis

Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

b)
COVID-19 ICU or HDU admission rate based on 81 NHS trusts for week 45.
SARI Watch data is provisional and subject to retrospective updates.

Please note the highlighted line corresponds to the UKHSA region in the subplot title, grey lines correspond to all other regions.
Figure 40: Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases reported through SARI Watch - a) fixed y-axis, b) adjusted y-axis

a) Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

b)
ECMO, SARI Watch

There were 3 new extra corporeal membrane oxygenation (ECMO) admissions reported in week 45 from the 7 Severe Respiratory Failure (SRF) centres in the UK. There was one admission, which was not related to an acute respiratory infection.

Please note that the other group includes other viral, bacterial or fungal ARI, suspected ARI, non-infection (such as asthma, primary cardiac, trauma) and sepsis of non-respiratory origin.

Figure 41: Laboratory confirmed ECMO admissions in adults (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK

SARI Watch data is provisional and subject to retrospective updates.
RSV admissions, SARI Watch

Data on hospitalisations, including ICU or HDU admissions, with respiratory syncytial virus (RSV) are shown below. RSV SARI Watch surveillance is sentinel. Please note that the SARI-Watch rates for 2023 to 2024 use the latest trust catchment population. For consistency the rates have been updated back to October 2020. The population denominator reflects changes in trust reconfiguration, hospital admission activity and population estimates.

In week 45, the overall hospital admission rate for RSV increased to 2.61 per 100,000 compared to 2.26 per 100,000 in the previous week. The highest rate was seen in the under 5 year olds at 35.1 per 100,000, which increased slightly from 32.2 per 100,000 in the previous week.

Figure 42: Weekly overall hospital admission rates (including ICU or HDU) of RSV positive cases per 100,000 population reported through SARI Watch, England

Please note that rates are based on the number of hospitalised cases divided by the Trust catchment population, multiplied by 100,000.
Figure 43: Weekly count hospital admissions of RSV positive cases reported through SARI Watch sentinel surveillance by level of care, England
Figure 44: Weekly hospitalisation (including ICU or HDU) admission rates by age group for RSV cases reported through SARI Watch, England - a) fixed y-axis, b) adjusted y-axis

Please note the highlighted line corresponds to the age group in the subplot title, grey lines correspond to all other age groups.

b)

SARI Watch data is provisional.
Mortality surveillance

COVID-19 deaths

For further information on COVID-19 related deaths in England please see the COVID-19 dashboard for death.

Daily excess all-cause mortality (England)

For further information on excess all-cause mortality in England please see the Fingertips excess mortality in England report, which uses Office for National Statistics (ONS) death registration data and the all-cause mortality surveillance report, which uses the European Mortality Monitoring (EuroMOMO) model to identify weeks with higher than expected mortality.
Influenza vaccination

Influenza vaccine uptake in GP patients

Weekly vaccine coverage data is provisional.

Up to week 45 of 2023, in 39.3% of GP practices reporting weekly to ImmForm for the main collection, the provisional proportion of people in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:

- 35.4% in under 65 years in a clinical risk group
- 27.4% in all pregnant women
- 74.2% in all those aged 65 years and over

**Figure 45: Cumulative weekly influenza vaccine uptake by target group in England**
In 2023 to 2024, all 2 and 3 year olds continue to be eligible for influenza vaccination through their GPs. Up to week 45 of 2023, in 93.4% of GP practices reporting weekly to ImmForm for the childhood collection, the provisional proportion of children in England who had received the 2023 to 2024 influenza vaccine in targeted groups was as follows:
• 36.1% in all 2 year olds
• 35.4% in all 3 year olds

Figure 46: Cumulative weekly influenza vaccine uptake in 2 and 3 year olds, in England
COVID-19 vaccination

COVID-19 vaccine uptake in England

The data for week 45 only includes information up to Friday, 10 November. This is due to delayed receipt of data files in time for extraction on Monday 13 November. The data for the most recent week is therefore incomplete. This will be corrected in the next weeks.

COVID-19 vaccinations began in England on 8 December 2020 during week 50 2020 (week ending 13 December 2020). Cumulative data up to the end of week 45 2023 (week ending 12 November 2023) was extracted from the National Immunisation Management Service (NIMS). The data presented this week is the provisional proportion of living people resident in England who had received COVID-19 vaccinations. Individuals vaccinated in England who have a registered address outside of England or where their address, age, or sex is unknown have been excluded. Due to changes in GP practice lists, in order to include newly registered patients and remove those who are no longer resident, there will be slight variation to the figures to reflect those who are currently resident in England.

Age is calculated as age on 31 March 2024. From 23 October 2023, data is extracted on a Monday with data capped to the previous Sunday. This change from Tuesday data extraction means that because of data lags, reported coverage for the most recent week is marginally lower than if data was extracted on Tuesday. This change has been implemented to help ensure timely reporting. All backing data is updated each week going back to the start of the programme.

Data is provisional and subject to change following further validation checks. There are significant changes being undertaken in the data feeds that provide these statistics. It is therefore necessary to report the autumn campaign on a fixed denominator, the population as at 31 August 2023. Any changes to historic figures will be reflected in the most recent publication. Please note that numbers published by UKHSA are for public health surveillance purposes only.

Autumn 2023 Campaign

Immunity derived from vaccination declines over time, Joint Committee on Vaccination and Immunisation (JCVI) has recommended an autumn 2023 campaign with the primary objective to boost immunity in those at higher risk from COVID-19 and thereby optimise protection against severe COVID-19, specifically hospitalisation and death in time for winter 2023 to 2024.

The autumn 2023 data reported below covers any dose administered from the 1 September 2024 provided there is at least 20 days from the previous dose. Eligible groups for the autumn campaign are defined in the COVID-19 healthcare guidance Green Book.

Table 4 presents coverage as measured against the total population and includes people who are not yet due to have their autumn 2023 booster, specifically those turning 65 years of age by the 31 March 2024. It is important that unvaccinated individuals, especially vulnerable adults,
receive a primary course of vaccination, irrespective of whether individuals have had previous infection. To understand the data in the context of vaccine waning across the whole COVID-19 programme, we present Table 5 which shows how recently a person who is living and resident in England has been vaccinated either through the primary vaccination campaign or a subsequent booster campaign.

By the end of week 45 of 2023 (week ending 12 November 2023), 65.8% (7,341,043 out of 11,164,326) of all people aged over 65 years who are living and resident in England who had been vaccinated with an autumn 2023 booster dose since 1 September 2023, Table 4 and Figure 47.

Table 4: Provisional cumulative people vaccinated by age with a dose of COVID-19 vaccine from the 1 September 2023 as part of the Autumn 2023 campaign in England

<table>
<thead>
<tr>
<th>National</th>
<th>People in NIMS cohort who are living and resident in England</th>
<th>Vaccinated since 1 September 2023*</th>
<th>Percentage vaccine uptake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over 80</td>
<td>3,010,182</td>
<td>2,129,511</td>
<td>70.7</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>2,458,682</td>
<td>1,745,648</td>
<td>71.0</td>
</tr>
<tr>
<td>70 to under 74</td>
<td>2,672,292</td>
<td>1,752,834</td>
<td>65.6</td>
</tr>
<tr>
<td>65 to under 70</td>
<td>3,023,170</td>
<td>1,713,050</td>
<td>56.7</td>
</tr>
<tr>
<td>Aged 65 years and over</td>
<td>11,164,326</td>
<td>7,341,043</td>
<td>65.8</td>
</tr>
</tbody>
</table>

*Autumn 2023 booster defined as any dose of vaccine given after 1 September 2023, provided there is an interval of at least 20 days since any previous dose.
Figure 47. Cumulative weekly COVID-19 vaccine uptake in those who are living and resident in England vaccinated with an Autumn 2023 dose since 1 September 2023

Please note that this graph shows data for the autumn 2022 campaign and does not correspond to the date axis but is aligned to the current autumn 2023 campaign to allow comparison of the rate of uptake in both campaigns.

Data for week 45 contain data only up to Friday 10 November 2023 and is therefore incomplete.
Proportion of people vaccinated by time since last vaccination

Table 5: Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago

<table>
<thead>
<tr>
<th>National</th>
<th>People in NIMS cohort who are living and resident in England</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vaccinated in the last 3 months (84 days)</td>
</tr>
<tr>
<td></td>
<td>Numbers vaccinated</td>
</tr>
<tr>
<td>Over 80</td>
<td>3,010,182</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>2,458,682</td>
</tr>
<tr>
<td>70 to under 75</td>
<td>2,672,292</td>
</tr>
<tr>
<td>65 to under 70</td>
<td>3,023,170</td>
</tr>
<tr>
<td>60 to under 65</td>
<td>3,691,023</td>
</tr>
<tr>
<td>55 to under 60</td>
<td>4,133,235</td>
</tr>
<tr>
<td>50 to under 55</td>
<td>4,127,778</td>
</tr>
<tr>
<td>45 to under 50</td>
<td>3,873,067</td>
</tr>
<tr>
<td>40 to under 45</td>
<td>4,410,433</td>
</tr>
<tr>
<td>35 to under 40</td>
<td>4,711,499</td>
</tr>
<tr>
<td>30 to under 35</td>
<td>4,788,980</td>
</tr>
<tr>
<td>25 to under 30</td>
<td>4,416,848</td>
</tr>
<tr>
<td>20 to under 25</td>
<td>3,787,791</td>
</tr>
<tr>
<td>18 to under 20</td>
<td>1,402,413</td>
</tr>
<tr>
<td>16 to under 18</td>
<td>1,430,176</td>
</tr>
<tr>
<td>12 to under 16</td>
<td>2,994,199</td>
</tr>
<tr>
<td>5 to under 12</td>
<td>4,998,730</td>
</tr>
</tbody>
</table>

Table 5 is presented to provide an overview of how recently a person has been vaccinated either through the primary vaccination campaign or subsequent booster campaigns. This helps us understand the data in the context of vaccine waning across the whole COVID-19 programme. Breakdowns by Ethnicity, and IMD, for those aged 65 and over can be found in the supplementary datafile.
For a regional breakdown of the ethnicity data is available in the accompanying data file for this report.

For COVID-19 data on the real-world effectiveness of the COVID-19 vaccines, and on COVID-19 vaccination in pregnancy, please see the COVID-19 vaccine surveillance reports.

For COVID-19 management information on the number of COVID-19 vaccinations provided by the NHS in England, please see the COVID-19 vaccinations webpage.

For UK COVID-19 daily vaccination figures and definitions, please see the Vaccinations’ section of the UK COVID-19 dashboard.

The population coverage data representing the evergreen offer of doses 1, 2, and 3 has changed little in recent months and are no longer presented in both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard. Both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard now highlight data on the most recent vaccination campaign in those at higher risk from COVID-19 as immunity derived from vaccination declines over time. The overall vaccine uptake in the living and resident population for those with at least dose 1, 2 and 3 doses is still available within the backing tables for this section and in the dashboard APIs.
International update

Global COVID-19 update

For further information on the global COVID-19 situation please see the World Health Organization (WHO) COVID-19 situation reports.

Global influenza update

For further information on the global influenza situation please see the World Health Organization (WHO) Influenza update.

Influenza in Europe

For further information on influenza in Europe please see the European Respiratory Virus Surveillance Summary weekly update.

Influenza in North America

For further information on influenza in the United States of America please see the Centre for Disease Control weekly influenza surveillance report. For further information on influenza in Canada please see the Public Health Agency weekly influenza report.

Influenza in Australia

For further information on influenza in Australia, please see the Australian Influenza Surveillance Report and Activity Updates.

Other respiratory viruses

Avian influenza and other zoonotic influenza

For further information, please see the Latest WHO update on 1 November 2023 and the Latest UKHSA avian influenza technical briefing 14 July 2023.

Middle East respiratory syndrome coronavirus (MERS-CoV)

For further information please see the WHO Disease Outbreak News Reports and the WHO publishes monthly updates.

Further information on management and guidance of possible cases is available online. The latest ECDC MERS-CoV risk assessment highlights that risk of widespread transmission of MERS-CoV remains very low.
Related links

Previous national COVID-19 reports
Previous weekly influenza reports
Annual influenza reports
COVID-19 vaccine surveillance reports
Previous COVID-19 vaccine surveillance reports
Public Health England (PHE) monitoring of the effectiveness of COVID-19 vaccination
Investigation of SARS-CoV-2 variants of concern: technical briefings
Sources of surveillance data for influenza, COVID-19 and other respiratory viruses
RCGP Virology Dashboard

UKHSA has delegated authority, on behalf of the Secretary of State, to process Patient Confidential Data under Regulation 3 The Health Service (Control of Patient Information) Regulations 2002

Regulation 3 makes provision for the processing of patient information for the recognition, control and prevention of communicable disease and other risks to public health.
About the UK Health Security Agency

UKHSA is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation health secure.

The UK Health Security Agency is an executive agency, sponsored by the Department of Health and Social Care.